Table 6.
Multivariate analysis of distant metastasis‐free survival (DMFS) according to posttreatment levels of BamHI A rightward transcripts encoded microRNA (miR‐BART)7‐3p, miR‐BART13‐3p, and Epstein‐Barr virus (EBV) DNA in patients with nasopharyngeal carcinoma
| Covariate | DMFS | |
|---|---|---|
| HR (95% CI) | P value | |
| EBV DNA | ||
| Undetectable | 1.00 | .039 |
| Detectable | 2.14 (1.04‐4.42) | |
| miR‐BART7‐3p | ||
| Undetectable | 1.00 | <.001 |
| Detectable | 4.13 (1.89‐9.01) | |
| miR‐BART13‐3p | ||
| Undetectable | 1.00 | .672 |
| Detectable | 1.19 (0.52‐2.72) | |
| Chemotherapy cycles | ||
| ≤3 | 1.00 | .762 |
| >3 | 0.89 (0.42‐1.90) | |
| Age (y) | ||
| ≤45 | 1.00 | .059 |
| >45 | 2.10 (0.97‐4.54) | |
| Gender | ||
| Male | 1.00 | .011 |
| Female | 0.25 (0.09‐0.73) | |
| Clinical stage | ||
| I‐II | 1.00 | .060 |
| III‐IV | 2.78 (0.96‐8.09) | |
Bold values indicate significance.
Abbreviations: CI, confidence interval; DMFS, distant metastasis‐free survival; HR, hazard ratio.